GoodRx Holdings, Inc. (GDRX) Stock — Forensic Analysis, Red Flags & Rating | Stockonomy · Stockonomy
Forensic Analysis · Technology / Software · as of Jul 2, 2026
GoodRx Holdings, Inc. (GDRX)
A forensic read on GoodRx Holdings, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
C · Mixed — selective
Forensic grade
Distress
Financial health
-0.2
Altman Z-score
Clean
Earnings quality
4
Forensic signals
47.9
P / E (ttm)
3.3%
ROE
$1.0B
Market cap
GoodRx Holdings, Inc. earns a C (Mixed — selective) forensic quality grade, and its Altman Z-score is -0.2, placing it in the Distress zone. 4 forensic signals were flagged in its latest SEC filings, led by receivables vs revenue.
What the filings flag
108d DSOReceivables vs revenue.Days sales outstanding moved from 67 to 108 days FY2024→FY2025 (receivables +62% vs revenue +1%). Receivables are outrunning sales — a flag for aggressive revenue recognition or slipping collections.
5%Return on invested capital.Return on invested capital is 5% and rising from 0% — well below its ~10% cost of capital, so reinvested dollars may be destroying value, not building it.
10% of revStock-based comp load.Stock-based compensation ran 10% of revenue and 47% of free cash flow in FY2025 — about $0.21 per diluted share. Heavy — a large slice of 'free cash flow' is really being paid out in stock, so the true owner cash per share is well below the headline.
132% of FCFShareholder returns.Returned $216M to shareholders (buybacks + dividends) in FY2025 — 132% of free cash flow. More than free cash flow generated — and beyond operating cash too, so the extra is coming from debt or cash reserves, which isn't sustainable indefinitely.
Key fundamentals
Net Margin3.8%
Debt / Equity0.79x
Free Cash Flow$164.4M
Latest Revenue$796.9M
Return on Equity4.9%
Revenue Growth YoY+0.6%
Go deeper — free with an account
The forensic grade and screens above are free — no account needed. An account adds the full interactive deep-dive on GoodRx Holdings, Inc.:
🔒The written investment read — what the numbers mean, in plain English
🔒Ask anything about GDRX's filings — AI Q&A across the 10-K, 10-Qs & 8-Ks
🔒Interactive valuation — reverse-DCF sliders, Monte Carlo & scenario stress
🔒Calibrated 12-month price forecast, with the math shown